Sanofi flunks Parkin­son's Phase II, ax­es hand­ful of mid-stage pro­grams in Q4 earn­ings

Bio­gen isn’t the on­ly one hit­ting road­blocks in Parkin­son’s.

Two days af­ter the big biotech re­vealed in year-end earn­ings that they cut a Phase II pro­gram for the neu­rode­gen­er­a­tive con­di­tion, Sanofi axed their own Phase II Parkin­son’s drug in its earn­ings an­nounce­ment. The tri­al failed at the end of Jan­u­ary, they said, al­though they will con­tin­ue de­vel­op­ing the com­pound, known as venglu­s­tat, in a hand­ful of rare dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER